Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
from FDA,2023.03
The price of generic capmatinib in LaosCapmatinib has been approved for the treatment of MET exon 14-mutated non-small cell lung cancer based on demonstrated efficacy in a patient ···【more】
Article source:Lucius LaosRelease date:2024-11-25Recommended:113
There are several generic versions of the Laos Lucius version of capmatinibMET dysregulation occurs in up to 26% of patients with non-small cell lung cancer (NSCLC) after treatment···【more】
Article source:Lucius LaosRelease date:2024-11-25Recommended:118
Capmatinib acts as a targeted therapy to stop the growth and spread of cancer cells by inhibiting MET tyrosine kinase activity. Usually, this medication is for those who do not res···【more】
Article source:Lucius LaosRelease date:2024-08-07Recommended:118
Capmatinib is a targeted drug manufactured by Novartis for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition···【more】
Article source:Lucius LaosRelease date:2024-08-07Recommended:122
Capmatinib prevents the growth and spread of cancer cells by inhibiting MET tyrosine kinase activity. Usually this medication is indicated for those patients who do not respond to ···【more】
Article source:Lucius LaosRelease date:2024-08-06Recommended:143
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: